DekaBank Deutsche Girozentrale
CCCC icon

DekaBank Deutsche Girozentrale’s C4 Therapeutics CCCC Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,800
Closed -$477K – 1372
2022
Q1 		$477K Buy
19,800
+1,800
+10% +$43.7K ﹤0.01% 1068
2021
Q4 		$593K Buy
+18,000
New +$712K ﹤0.01% 1060

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

DekaBank Deutsche Girozentrale's CCCC Position: Q2 2022 in Review

DekaBank Deutsche Girozentrale sold out of C4 Therapeutics (CCCC) in Q2 2022, closing a stake of 19,800 shares — an estimated $477K sold.

DekaBank Deutsche Girozentrale first reported a position in CCCC in Q4 2021 and held it in 2 quarters. The position peaked at $593K in Q4 2021. 113 funds tracked by Wall St. Rank hold CCCC as of Q2 2022.

  • DekaBank Deutsche Girozentrale reported no remaining C4 Therapeutics position as of Q2 2022 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 19,800 C4 Therapeutics shares in Q2 2022, an estimated $477K.
  • DekaBank Deutsche Girozentrale first reported a position in C4 Therapeutics in Q4 2021 and held it in 2 quarters.
  • DekaBank Deutsche Girozentrale's C4 Therapeutics position peaked at $593K in Q4 2021.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2022.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2022, filed 3 Aug 2022.